

infections in the next two decades. There is a possibility that Japan, as well as any country in the world, will suffer from resurgent HBV infection that might be inapparent in the general population. During 35 years from 1971 to 2005, a city hospital in the Metropolitan Tokyo was visited by 4,430 patients infected with HBV. Patients with acute and chronic infections increased since 1996, thereby indicating that HBV infection has not been controlled efficiently in Japan.

## MATERIALS AND METHODS

### Patients

During 35 years from 1971 through 2005, 4,430 patients with HBV infection visited the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo, including 153 with acute and 4,277 with chronic HBV infection. Genotypes were A in 158 (3.6%) patients, B in 521 (11.8%), C in 3,564 (80.5%), D in 7 (0.2%), F in 3 (0.06%), H in 2 (0.04%) and not typeable in the remaining 175 (3.9%) patients. The median age of the patients was 37 years (range: 0.1–83) at the presentation, and included 3,210 (72.1%) men. Acute infection was diagnosed by high-titered antibody to hepatitis B core antigen of the IgM class and/or the development of HBsAg in previously seronegative individuals. Chronic hepatitis was diagnosed by liver biopsy carried out by laparoscopy and/or ultrasonic images, and liver cirrhosis by liver biopsy and/or ultrasonographic images plus laparoscopic findings. The number of patients with acute and chronic hepatitis B changed through 35 years, and the genotypes/subgenotypes were surveyed for predicting future trends of HBV infection in Japan. The study design conformed to the 1975 Declaration of Helsinki, and was approved by the Ethics Committee of the institution. Every patient gave an informed consent for this study.

### Markers of HBV Infection

HBsAg and the corresponding antibody (anti-HBs) were determined by hemagglutination (MyCell, Insti-

tute of Immunology Co., Ltd., Tokyo, Japan), and HBeAg by enzyme-linked immunosorbent assay (F-HBe, Sysmex, Kobe, Japan). HBV DNA was determined by the polymerase chain reaction (PCR) followed by hybridization (Amplicor HBV Monitor, Roche Molecular Systems, Inc., Branchburg, NJ) and the results were expressed in log copies/ml over a range from 2.6 to 7.6. HBV genotypes (A–H) were determined by enzyme-linked immunosorbent assay (HBV GENOTYPE EIA, Institute of Immunology) [Usuda et al., 1999, 2000] and PCR-Invader assay with genotype-specific probes [Tadokoro et al., 2006]. Subgenotypes of A, B and C were determined by sequence analysis, restriction fragment length polymorphism [Sugauchi et al., 2004a, 2004b; Tanaka et al., 2005] and PCR-Invader assay [Tadokoro et al., 2006].

### Statistical Analysis

Frequencies were compared between groups by the Chi-squared test and Fisher's exact test, and medians by the Mann-Whitney's *U*-test. Analysis of data was conducted with the computer program SPSS ver.11.0 (SPSS Inc., Chicago, IL). The trend of subgenotypes B1/Bj and B2/Ba was analyzed by the Cochran-Armitage trend test with SAS version 9.1.3 software (SAS Institute, Inc., Cary, NC). A *P* value less than 0.05 was considered significant.

## RESULTS

### Patients With HBV Infection During 35 Years (1971–2005)

During 35 years from 1971 through 2005, the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo was visited by 4,430 patients infected with HBV, including 153 with acute and 4,277 with chronic infection. Table I compares the demographic, clinical and virological characteristics between the patients with acute and chronic HBV infection at the baseline. Patients with acute HBV infection were younger ( $P = 0.046$ ), predominantly male ( $P = 0.004$ ), had higher alanine aminotransferase levels ( $P < 0.001$ ),

TABLE I. Baseline Characteristics of Patients Infected With HBV Who Visited Toranomon Hospital During 35 Years (1971–2005)

Features <sup>a</sup>	Acute infection (n = 153)	Chronic infection (n = 4,277)	Differences ( <i>P</i> value)
Age in years	34 (19–69)	38 (0.1–83)	0.046
<39	99 (65%)	2,358 (55%)	
40–59	49 (32%)	1,642 (38%)	
≥60	5 (3%)	277 (7%)	
Men	125 (82%)	3,067 (72%)	0.004
ALT (IU/L)	1,460 (19–6,876)	58 (12–3,520)	<0.001
Sexual transmission	102 (67%)	129 (3%)	<0.001
Liver disease			
Symptom-free	0	1,035 (24%)	
Chronic hepatitis	0	2,617 (61%)	
Cirrhosis	0	405 (10%)	
Hepatocellular carcinoma	0	220 (5%)	
HBsAg	100 (65%)	2,131 (50%)	<0.001
HBV DNA (log copies/ml)	5.9 (<2.6 to >7.6)	6.4 (<2.6 to >7.6)	0.014

<sup>a</sup>Data are expressed in number of patients with percentage in parentheses or the median value with a range in parentheses.

were positive more frequently for HBeAg ( $P < 0.001$ ), and had lower HBV DNA loads ( $P = 0.014$ ) than those with chronic infection. Sexual transmission was more frequent in patients with acute than chronic HBV infection (67% vs. 3%,  $P < 0.001$ ).

The number of new patients presenting with acute and chronic HBV infections during a 5-year period was compared during 1971 through 2005 (Fig. 1). In the initial four 5-year periods (1971–1990), both patients with acute and chronic HBV infections increased linearly. In the fifth 5-year period (1991–1995), however, patients with acute or chronic HBV infection decreased to less than those in the previous 5-year period (1986–1990). In the next 5-year period (1996–2000), nevertheless, patients with acute HBV infection began to increase while a decrease in chronic HBV infection was observed. In the seventh 5-year period (2001–2005), patients with acute HBV infection kept increasing. In addition, there was a small but appreciable increase of patients with chronic HBV infection in comparison with the previous 5-year period (1996–2000). Taken altogether, acute HBV infection resurged since 1991 accompanied by an increase in chronic HBV infection since 2001.

#### HBV Genotypes in Patients Infected With HBV

HBV was typeable in 126 of the 153 (82.4%) patients with acute and 4,121 of the 4,277 (96.4%) with chronic HBV infection (Table II). Genotype A, foreign to Japan, was more frequent in acute than chronic HBV infection (28.6% vs. 3.0%,  $P < 0.001$ ). There were no differences in the distribution of endemic genotypes B and C; combined, they accounted for 69.8% and 96.8%, respectively, in patients with acute and chronic HBV infections. Foreign genotypes other than A (D–H) were detected in 2 (1.6%) and 10 (0.24%) patients with acute and chronic HBV infections, respectively. One each genotype D and H were found in patients with acute HBV infection; and 6 with genotype D, 3 genotype F and 1 genotype H in those chronic infection. Among patients with chronic HBV infection, genotype B was more frequent

TABLE II. Distribution of Genotypes in Patients With Acute and Chronic HBV Infections

Genotypes <sup>a</sup>	Acute (n = 126)	Chronic (n = 4,129)	Differences (P value)
A	36 (28.6%)	122 (3.0%)	<0.001
B	13 (10.3%)	508 (12.3%)	NS
C	75 (59.5%)	3,489 (84.5%)	NS
D	1 (0.8%)	6 (0.1%)	NS
E	0	0	NS
F	0	1 (0.02%)	NS
G	0	0	NS
H	1 (0.8%)	3 (0.07)	NS

<sup>a</sup>Data are expressed in number of patients with percentage in parentheses.

(566/3,481 [16.3%] vs. 28/508 [5.5%],  $P < 0.001$ ), while genotype C was less common (2,915/3,481 [83.7%] vs. 480/508 [94.5%],  $P < 0.001$ ), in those with chronic hepatitis than cirrhosis and/or HCC.

#### Subgenotypes of HBV

Subgenotypes of A, B, and C were determined in patients with HBV infection. Of the 158 patients infected with genotype A, 15 (9.5%) were classified into subgenotype A1/Aa and 121 (76.6%) into A2/Ae; the remaining 22 (13.9%) were not typeable. Likewise, of the 521 patients with genotype B, 388 (74.5%) were infected with the domestic subgenotype B1/Bj and 102 (19.6%) with foreign subgenotype B2/Ba; subgenotypes in the remaining 31 (6%) patients could not be determined. Figure 2 compares the proportion of these subgenotypes among the seven 5-year periods. By the trend analysis, subgenotype B2/Ba was increasing recently ( $P < 0.05$ ). Subgenotypes of C were domestic C2/Cs in all the 1,610 HBV isolates tested. The foreign subgenotype C1/Ce was not detected in any patient infected with HBV genotype C.

#### Change in the Distribution of Genotypes in Patients Infected With HBV

Figure 3 illustrates distributions of genotypes A–C in patients with acute and chronic HBV infection during




Fig. 1. Patients with acute and chronic HBV infection who visited Toranomon Hospital during 35 years from 1971 to 2005. Numbers are indicated in different scales for patients with acute and chronic HBV infections for seven 5-year periods.




Fig. 2. Distribution of subgenotypes of genotype B shifting during 1971 through 2005. The number of patients is shown in parentheses for each seven 5-year period.

seven 5-year periods. The genotype distribution in patients with acute HBV infection changed through seven 5-year periods. The proportion of genotype A started to increase sharply in the fifth 5-year period (1996–1999) and accounted for 43% and 40%, respectively, in the sixth (1996–2000) and seventh (2001–2005) 5-year periods. The proportion of genotype A during the fifth and seventh 5-year periods (1991–2005) was significantly higher than that during the second through fourth 5-year periods (1976–1990) (39% [33/84] vs. 8% [3/40],  $P < 0.001$ ). Before 1995, genotype A was detected in men  $< 35$  years but not found in those  $> 36$  years (7/21 [33%] vs. 0/25 [0%]). However, genotype A became comparably frequent since 1996 (15/29 [52%] vs. 14/32 [44%]).

By remarkable contrast, the distribution of genotypes in patients with chronic HBV infection remained fairly constant, although the proportion of genotypes A kept increasing constantly. Thus the proportion of genotype A during the fifth through seventh 5-year periods (1991–2005) was greater than that during the first to

fourth 5-year periods (1971–1990) (4.3% [70/1,638] vs. 2.4% [51/2,128],  $P < 0.001$ ).

## DISCUSSION

The Department of Hepatology at the Toranomon Hospital was visited by 153 with acute and 4,277 patients with chronic HBV infection during 35 years from 1971 through 2005. Patients with acute HBV infection were younger, more commonly male and had been infected by sexual contact more frequently than those with chronic infection. Patients were grouped by the year when they visited the department, and they were compared among seven 5-year periods spanning 1971–2005, for the purpose of estimating time-dependent trends of acute and chronic HBV infections in Japan.

Remarkably, patients presenting with acute HBV infection increased during the past 35 years (Fig. 1). Patients with chronic HBV infection peaked in 1986–1990 and then decreased until 1996–2000. They did not decrease further, but instead, increased slightly in the 21st century. Such a recent increase in chronic HBV infection would reflect resurgence of acute infection, which is supported by the analysis of genotypes.

The distribution of HBV genotypes was much different between patients with acute and chronic infections. Of note, infection with genotype A was much more frequent in acute than chronic infection (28.6% vs. 3%,  $P < 0.001$ ). HBV genotypes have distinct geographic distribution [Miyakawa and Mizokami, 2003; Fung and Lok, 2004; Norder et al., 2004]. The Japanese have been infected with genotypes B and C since the prehistoric era [Yamashita et al., 1975], and foreign genotypes represented by A (both subgenotypes A1/Aa and A2/Ae) were introduced by travelers and immigrants after the end of World War II. Since 1991, foreign genotypes have been increasing in acute HBV infection in Japan [Sugauchi et al., 2006]. As for chronic HBV infection, genotype C was more prevalent in patients with cirrhosis and/or HCC than in those with chronic hepatitis (480/508 [94.5%], vs. 2,915/3,481 [83.7%],  $P < 0.001$ ), standing in corroboration with previous studies [Kao et al., 2000; Orito et al., 2001].

There was a dramatic change in the distribution of HBV genotypes in patients with acute HBV infection during the past 35 years. This change is attributed to ever increasing infection with genotype A in them. It accounted for only 8.1% before 1990, in marked contrast to 39.3% after 1991 ( $P < 0.001$ ). The recent resurgence of acute infection in Japan could be due to increase in the transmission with HBV of foreign genotypes. The gradual increase of genotype A, in patients with chronic HBV infection since 2001, would be accounted for by an increase of acute infection with this genotype in Japan. In support of this view, infection with genotype A tends to persist, infection even in adulthood, and becomes chronic in 10% of infected adults [Suzuki et al., 2005; Kobayashi et al., 2006]. In an outbreak transmitted by a surgeon, 5 of the 16 (31%) patients infected with genotype A became HBV carriers [Harpaz et al., 1996].




Fig. 3. Time-dependent distribution of HBV genotypes in patients with acute and chronic HBV infections during 1971 through 2005. Distribution of genotypes A–C in patients with acute HBV infection (A) and those with chronic HBV infection (B) are shown for seven 5-year periods. The number of patients is shown in parentheses for each seven 5-year period.

There are two types of risk for exposure to HBV. One is avoidable and mediated by promiscuous sexual contacts and the use of illicit intravenous drugs. The other is not preventable and can involve citizens without high-risk behaviors. For instance, HBV can be transmitted from patient to patient in dental care [Redd et al., 2007]. HBV can spread from carrier surgeons who are negative for serum HBeAg [Perry et al., 2006]. In 2002, the largest outbreak of HBV involving 38 patients occurred in a physician's office in New York City by multidose vials contaminated with HBV [Samandari et al., 2005]. There is a pressing need to investigate and determine the risk of HBV transmission in the health care setting [Allos and Schaffner, 2007]. Fortunately, risks of HBV infection can be avoided by vaccination. Mass vaccination of newborns and catch-up vaccination, such as those conducted in the United States [MMWR, 2002], Taiwan [Ni et al., 2001] and elsewhere, would need to be considered in Japan. The ultimate national protection would be universal vaccination of all age groups.

In conclusion, acute HBV infection is increasing in Japan in spite of immunoprophylaxis of high-risk babies implemented nationally since 1986. Based on genotypes/subgenotypes changing with time, the increase may be attributed to infections with HBV of foreign genotypes/subgenotypes predominantly by sexual contact. Since HBV genotype A, with a high propensity to persist, prevailed in acute infection, chronic infection would increase in the foreseeable future. Effective measures have to be taken for preventing HBV transmission among young men at high risk in Japan.

## REFERENCES

- Allos BM, Schaffner W. 2007. Transmission of hepatitis B in the health care setting: The elephant in the room or the mouse? *J Infect Dis* 195:1245–1247.
- Fung SK, Lok AS. 2004. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? *Hepatology* 40:790–792.
- Harpaz R, Von Seidlein L, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulos K, Lambert SB, Robertson BH, Cherry JD, Shapiro CN. 1996. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. *N Engl J Med* 334:549–554.
- Kao JH, Chen PJ, Lai MY, Chen DS. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 118:554–559.
- Kobayashi M, Akuta N, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Saitoh S, Kobayashi M, Someya T, Sato J, Watabiki S, Miyakawa Y, Kumada H. 2006. Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. *J Med Virol* 78:60–67.
- Koyama T, Matsuda I, Sato S, Yoshizawa H. 2003. Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy. *Hepatol Res* 26:287–292.
- Lee WM. 1997. Hepatitis B virus infection. *N Engl J Med* 337:1733–1745.
- Miyakawa Y, Mizokami M. 2003. Classifying hepatitis B virus genotypes. *Intervirology* 46:329–338.
- MMWR. 2002. Hepatitis B vaccination—United States, 1982–2002. *Morb Mortal Wkly Rep* 51:549–552, 563.
- MMWR. 2004. Incidence of acute hepatitis B—United States, 1990–2002. *Morb Mortal Wkly Rep* 52:1252–1254.
- Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS. 2001. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 135:796–800.
- Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnus LO. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 47:289–309.
- Noto H, Terao T, Ryou S, Hirose Y, Yoshida T, Ookubo H, Mito H, Yoshizawa H. 2003. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during 1980–1994. *J Gastroenterol Hepatol* 18:943–949.
- Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. 1976. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. *N Engl J Med* 294:746–749.
- Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S. 2001. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. *Japan HBV Genotype Research Group. Hepatology* 33:218–223.
- Perry JL, Pearson RD, Jagger J. 2006. Infected health care workers and patient safety: A double standard. *Am J Infect Control* 34:313–319.
- Redd JT, Baumbach J, Kohn W, Nainan O, Khristova M, Williams I. 2007. Patient-to-patient transmission of hepatitis B virus associated with oral surgery. *J Infect Dis* 195:1311–1314.
- Samandari T, Malakmadze N, Balter S, Perz JF, Khristova M, Swetnam L, Bornschlegel K, Phillips MS, Poshni IA, Nautiyal P, Nainan OV, Bell BP, Williams IT. 2005. A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office. *Infect Control Hosp Epidemiol* 26:745–750.
- Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. 2004a. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 85:811–820.
- Sugauchi F, Kumada H, Sakugawa H, Komatsu M, Niitsuuma H, Watanabe H, Akahane Y, Tokita H, Kato T, Tanaka Y, Orito E, Ueda R, Miyakawa Y, Mizokami M. 2004b. Two subtypes of genotype B (Ba and B<sub>2</sub>) of hepatitis B virus in Japan. *Clin Infect Dis* 38:1222–1228.
- Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang JH, Toyoda J, Kuramitsu T, Suzuki K, Tanaka E, Akahane Y, Ichida T, Izumi N, Inoue K, Hoshino H, Iino S, Yotsuyanagi H, Kakumu S, Tomita E, Okanoue T, Nishiguchi S, Murawaki Y, Hino K, Onji M, Yatsushashi H, Sata M, Miyakawa Y, Ueda R, Mizokami M. 2006. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatol Res* 36:107–114.
- Suzuki Y, Kobayashi M, Ikeda K, Suzuki F, Arfaee Y, Akuta N, Hosaka T, Saitoh S, Kobayashi M, Someya T, Matsuda M, Sato J, Watabiki S, Miyakawa Y, Kumada H. 2005. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. *J Med Virol* 76:33–39.
- Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyuchi S, Egashira T, Kumada H. 2006. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. *J Virol Methods* 138:30–39.
- Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, Yoshizawa H. 2004. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995–2000. *Intervirology* 47:32–40.
- Tanaka Y, Orito E, Yuen MF, Mukaida M, Sugauchi F, Ito K, Ozasa A, Sakamoto T, Kurbanov F, Lai CL, Mizokami M. 2005. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. *Hepatol Res* 33:216–224.
- Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods* 80:97–112.
- Usuda S, Okamoto H, Tanaka T, Kidd-Ijunggren K, Holland PV, Miyakawa Y, Mayumi M. 2000. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. *J Virol Methods* 87:81–89.
- Yamashita Y, Kurashina S, Miyakawa Y, Mayumi M. 1975. South-to-north gradient in distribution of the r determinant of hepatitis B surface antigen in Japan. *J Infect Dis* 131:567–569.

## Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Hitomi Sezaki · Fumitaka Suzuki · Yusuke Kawamura · Hiromi Yatsuji ·  
Tetsuya Hosaka · Norio Akuta · Masahiro Kobayashi · Yoshiyuki Suzuki ·  
Satoshi Saitoh · Yasuji Arase · Kenji Ikeda · Yuzo Miyakawa ·  
Hiromitsu Kumada

Received: 30 March 2008 / Accepted: 22 August 2008  
© Springer Science+Business Media, LLC 2008

**Abstract** *Background* Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully. *Aim* The influence of gender and age on treatment with pegylated interferon (PEG-IFN) and ribavirin was evaluated in a retrospective study. *Methods* PEG-IFN and ribavirin were given for 48 weeks to 179 men and 121 women infected with hepatitis C virus (HCV) of genotype 1b in high viral loads (>100 kIU/ml). *Results* Sustained virological response at 24 weeks after treatment was poorer in women than men who were aged  $\geq 50$  years (22% vs 53%,  $P < 0.001$ ). Among the patients aged  $\geq 50$  years who had received  $\geq 80\%$  of the doses of PEG-IFN, ribavirin, or both, women responded less often than men (26% vs 64%,  $P < 0.001$ ; 33% vs 61%,  $P = 0.022$ ; and 32% vs 63%,  $P = 0.016$ ; respectively). In multivariate analysis, male gender, retention of indocyanine green, ribavirin dose and compliance with therapy increased sustained virological response. *Conclusions* Response to combined PEG-IFN and ribavirin is poorer in female than male patients with hepatitis C who are aged  $\geq 50$  years, irrespective of compliance with treatment. Low estrogen levels in older women could be responsible for their impaired response to PEG-IFN and ribavirin.

**Keywords** Aging · Women · Chronic hepatitis C · Genotypes · Interferon · Ribavirin

### Introduction

There are an estimated 170 million people worldwide that are chronically infected with hepatitis C virus (HCV) [1]. HCV can persist in 70–80% of individuals who have been exposed to it, and it can induce chronic liver disease, through cirrhosis to hepatocellular carcinoma (HCC) in approximately 30% of them until 30–40 years after they were infected [2–4]. A number of viral and host factors influence the velocity of fibrosis progression in chronic hepatitis C. Thus, stage and grade of hepatitis are more severe in patients who are infected with HCV genotype 1 in high viral loads [5–7]. Male gender, age and intake of alcohol accelerate fibrosis, as well [8–10].

Interferon (IFN) combined with ribavirin has been the most effective and favored treatment of chronic hepatitis C to date. The combined treatment with the standard IFN can terminate HCV-1 infection with high viral loads in approximately 20% [11], and that with pegylated IFN (PEG-IFN) in >40% [12]. Owing to hemolytic side effects, however, women are less tolerant to ribavirin [13]. Although the response to combined treatment has been shown to be better in women than in men in previous studies, there remains a possibility that it could be influenced by age. Hence, there is a need for the comparison of the response between men and women in different age groups.

Virological response to PEG-IFN and ribavirin at the end of a 48-week treatment (ETR), as well as sustained virological response (SVR) 24 weeks after the completion of therapy, was compared between 179 men and 121

H. Sezaki (✉) · F. Suzuki · Y. Kawamura · H. Yatsuji ·  
T. Hosaka · N. Akuta · M. Kobayashi · Y. Suzuki · S. Saitoh ·  
Y. Arase · K. Ikeda · H. Kumada  
Department of Hepatology, Toranomon Hospital, Minato-ku,  
Tokyo 105-8470, Japan  
e-mail: hitomis@mx1.harmonix.ne.jp

Y. Miyakawa  
Miyakawa Memorial Research Foundation, Tokyo, Japan

women who were infected with HCV-1b in high viral loads. In patients aged  $\geq 50$  years, both ETR and SVR were poorer in women than in men, irrespective of the total dose of IFN, ribavirin or both.

## Methods

### Study Population

From December 2001 to February 2006, 490 consecutive patients with chronic hepatitis C received combination therapy with PEG-IFN and ribavirin at the Department of Hepatology in the Toranomon Hospital in Metropolitan Tokyo. The following inclusion criteria were met by 300 (61%) patients: they were (1) positive test results for antibodies to HCV (anti-HCV) and for HCV RNA genotype 1b by qualitative methods, and not co-infected with HCV of other genotypes; (2) negative test results for hepatitis B surface antigen or antibodies to human immunodeficiency virus type-1 (HIV-1); (3) confirmed findings of high HCV RNA levels  $\geq 100$  kIU/ml, which is the Japanese definition of high viral loads [14, 15], within the past 2 months; (4) no cirrhosis diagnosed by laparoscopy and ultrasonography, and with platelet counts  $>80 \times 10^3/\text{mm}^3$ ; (5) body weight  $\geq 40$  kg and not pregnant or lactating; (6) total alcohol intake  $<500$  kg in the past; (7) no HCC, hemochromatosis, Wilson's disease, primary biliary cirrhosis, alcoholic hepatitis or autoimmune hepatitis; (8) no treatment with antivirals or immunosuppressants during the previous 3 months; and (9) with the wish to comply with the treatment protocol for 48 weeks. None of them received growth factors before or during the study period.

The 300 patients, comprising 179 men and 121 women, received PEG-IFN and ribavirin for 48 weeks and were followed for at least 24 weeks after completion of this combination therapy. Informed consent was obtained from each patient, and the study protocol conformed to the ethics guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

### Serum Markers of HCV Infection

Anti-HCV was determined by third-generation enzyme-linked immunosorbent assay (ELISA) by commercial kits (Ortho HCV Ab ELISA Test 3; Chiron Cooperation, Emeryville, CA, USA). HCV RNA was determined quantitatively by polymerase chain reaction (PCR) (Cobas Amplicor HCV Monitor ver. 2.0, Roche Diagnostics, Tokyo, Japan) in serum diluted tenfold at the baseline, as well as at least monthly during and after treatment; it has a dynamic range between 5 kIU/ml and 5,000 kIU/ml. Sera

negative for HCV RNA ( $<5$  kIU/ml) by quantitative assay were tested by qualitative PCR (Amplicor, Roche Molecular Systems, Inc., Branchburg, NJ, USA) with a detection limit at 100 copies/ml.

### Combined PEG-IFN and Ribavirin Therapy

Patients underwent subcutaneous administration of PEG-IFN- $\alpha 2b$  (PEG-Intron, Schering-Plough Corp, Kenilworth, NJ, USA), weekly, at a median dose of 1.4  $\mu\text{g}/\text{kg}$  (range 0.8–1.9  $\mu\text{g}/\text{kg}$ ), together with ribavirin orally, at a median daily dose of 11 mg/kg (range 3.7–14.2 mg/kg) for 48 weeks. The dose of ribavirin was adjusted by body weight: 600 mg for patients weighing  $\leq 60$  kg; 800 mg for those between  $>60$  kg and  $<80$  kg; and 1,000 mg for those  $\geq 80$  kg. It was tapered in the 99 (33%) patients in whom hemoglobin levels decreased below 10 g/dl during the combination therapy.

### Statistical Analysis

Variables were compared between groups by the chi-square test, Fisher's exact probability test and the Mann-Whitney U test. Differences in the loss of HCV RNA from the serum between groups was evaluated with the Kaplan-Meier life table with use of the log rank test. The influence of various factors on the response to PEG-IFN/ribavirin was evaluated by logistic regression in univariate and multivariate analyses. Analysis of all data was performed with the computer program SPSS software (SPSS Inc., Chicago, IL, USA), and a *P* value less than 0.05 was considered significant.

## Results

### Baseline Characteristics of Male and Female Patients Infected with HCV-1b in High Loads

PEG-IFN and ribavirin were given for 48 weeks to 179 men and 121 women who had been infected with HCV-1b in high viral loads ( $>100$  kIU/ml). Table 1 compares baseline characteristics between them. Women were older, had lower hemoglobin values and platelet counts, and lower levels of albumin, gamma-glutamyl-transpeptidase ( $\gamma$ -GTP) and ferritin, than men. The stage of fibrosis was lower in women than in men, although their alanine aminotransferase (ALT) levels were comparable. Three months before the start of combination therapy, IFN had been given to 75 (42%) of the 179 male patients, comparably frequently to 40 of the 121 (33%) female patients. Age distribution for men and women is shown in Fig. 1. The proportion of patients  $\geq 60$  years was higher in women than in men (39% vs 19%, *P* < 0.001).


**Table 1** Baseline characteristics of 300 patients with chronic hepatitis with high-titers of HCV-1b RNA who had received PEG-IFN and ribavirin for 48 weeks and were followed for 48 weeks or longer

Characteristic*	Men (n = 179)	Women (n = 121)	Differences P
Age (years)	50 (19–66)	57 (30–69)	<0.001
Previous IFN treatment	75 (42%)	40 (33%)	0.146
Hemoglobin (g/dl)	15.2 (11.5–17.8)	13.5 (11.2–15.1)	<0.001
Platelets ( $\times 10^3/\text{mm}^3$ )	176 (88–366)	165 (91–331)	0.025
Albumin (g/dl)	3.9 (3.2–4.6)	3.8 (3.0–4.6)	0.004
ALT (IU/l)	77 (23–504)	68 (19–391)	0.078
$\gamma$ -GTP (IU/l)	78 (14–409)	37 (11–171)	0.011
LDL (mg/dl)	98 (50–176)	99 (57–168)	0.920
Ferritin (mg/l)	186 (<10–1,327)	95 (<10–442)	<0.001
ICG <sub>15</sub> (%)	14 (4–41)	13 (2–31)	0.969
Stage (F0–1/F2–3)	80/66 (50 unknown)	42/55 (57 unknown)	0.050

ALT alanine aminotransferase,  $\gamma$ -GTP gamma-glutamyl transpeptidase, LDL low density lipoprotein, ICG<sub>15</sub>, retention of indocyanine green at 15 min


\* The means (ranges) are given

**Fig. 1** Distribution of ages in the male and female patients with chronic hepatitis C who were infected with HCV-1b in high loads




#### Virological Response During the 48-Week Treatment with PEG-IFN and Ribavirin

On-treatment response to the combined treatment is compared between men and women in Fig. 2. Through 48 weeks on treatment, women gained a virological response less frequently than did men. ETR was achieved by 58% of women as against 83% of men ( $P < 0.001$ ). Restricted to the patients who gained ETR, women lost HCV RNA from serum later than men did [median (range) 24.1 (2.0–36.4) vs 13.0 (2.0–48.0) weeks,  $P < 0.001$ ]. Figure 3 depicts the on-treatment virological response in patients  $<50$  years and those  $\geq 50$  years separately. The virological response was no different between men and women  $<50$  years. However, it was poorer in women than



**Fig. 2** On-treatment virological responses to PEG-IFN and ribavirin in male and female patients infected with HCV-1b in high viral loads

**Fig. 3** On-treatment virological responses to combined IFN and ribavirin in male and female patients infected with HCV-1b in high viral loads who were less than 50 years (a) or 50 years or older (b)




in men  $\geq 50$  years. Differences between men and women in total (Fig. 2), therefore, were attributed to a poorer response of women  $\geq 50$  years to the combined treatment.

#### Sustained Virological Response to the 48-Week Treatment with PEG-IFN and Ribavirin

Sustained virological response 24 weeks after the completion of combined treatment was accomplished much less frequently in women than in men [33/121 (27%) vs 105/179 (59%),  $P < 0.001$ ]. SVR was influenced by age both in men and in women (Fig. 4). It was found significantly less often in women than men who were 50 years or older.

Figure 5 illustrates the relationship between the earliest on-treatment virological response and SVR in men and women. Patients with a virological response at 4 weeks gained SVR invariably. However, in the patients with virological response in later weeks, SVR was achieved less frequently in women than in men. In the patients who had lost HCV RNA from the serum at 12 weeks, in particular, SVR was achieved significantly less often in women than in men (63% vs 88%,  $P = 0.012$ ). The relationship




**Fig. 5** Sustained virological response in male and female patients who lost HCV RNA from the serum at various weeks on treatment with PEG-IFN and ribavirin

between on-treatment virological response and SVR was compared among women in different age groups (Fig. 6). In the patients with the earliest virological response at 12 weeks and 24 weeks, SVR was achieved less frequently in women aged  $\geq 50$  years than in those  $< 50$  years, but the difference fell short of being significant due to the small numbers of patients in the comparison.

#### SVR and Compliance with PEG-IFN Therapy, Ribavirin Therapy, or Both


Table 2 compares compliance with the combined treatment between men and women. Either or both of PEG-IFN and ribavirin were tolerated to a lesser extent by women than by men. Thus, doses  $\geq 80\%$  were reached less frequently in women than in men for PEG-IFN or ribavirin, or both. The initial dose of ribavirin was no different between men and women.

SVR was achieved less frequently in women than in men who had received  $\geq 80\%$  of the dose of PEG-IFN



**Fig. 4** Sustained virological response to PEG-IFN and ribavirin in male and female patients stratified by age. The number of patients is indicated in parentheses in each column






**Fig. 6** Sustained virological response to PEG-IFN and ribavirin in female patients stratified by age who lost HCV RNA from serum at various weeks on treatment

**Table 2** PEG-IFN and ribavirin received by patients with chronic hepatitis with high-titers of HCV-1b RNA

PEG-IFN and ribavirin	Men (n = 179)	Women (n = 121)	Differences P
Initial ribavirin dose (mg/kg body weight)	11.1 (5.0–14.1)	11.2 (3.7–14.3)	0.735
Total dose			
PEG-IFN ≥ 80%	139 (78%)	94 (53%)	<0.001
Ribavirin ≥ 80%	117 (65%)	42 (35%)	<0.001
Both ≥ 80%	110 (61%)	32 (27%)	<0.001
Withdrawn	28 (16%)	28 (23%)	0.131

[20/64 (31%) vs 92/138 (67%),  $P < 0.001$ ], ribavirin [19/42 (45%) vs 79/120 (66%),  $P = 0.027$ ] or both [13/32 (41%) vs 72/109 (66%),  $P = 0.013$ ]. Again, differences were observed only in patients  $\geq 50$  years (Fig. 7). In the patients  $< 50$  years, in contrast, the rate of SVR was no different between women and men who had received  $\geq 80\%$  of the dose of PEG-IFN, ribavirin, or both.

**Fig. 7** Sustained virological response to PEG-IFN and ribavirin in patients who had received 80% or more of the dose of IFN (a), ribavirin (b) or both of them (c). Results are shown for men and women in two age groups



The influence of age was compared between male and female patients in different age groups. SVR was achieved significantly more frequently in the men aged  $\geq 60$  years [88/145 (61%) vs 17/74 (37%),  $P = 0.001$ ] and  $< 60$  years [17/34 (50%) vs 6/48 (13%),  $P < 0.001$ ]. Likewise, SVR was more common in male than female patients aged 50–59 years [33/60 (55%) vs 16/53 (30%),  $P = 0.013$ ].

#### Multivariate Analysis for Factors Accelerating the Response to PEG-IFN and Ribavirin Therapy

In univariate analysis, age, gender, hemoglobin, albumin, ICG<sub>15</sub>, ribavirin dose and compliance with PEG-IFN therapy, ribavirin therapy, or both, influenced SVR. In multivariate analysis, only male gender, ICG<sub>15</sub>, ribavirin dose and compliance with PEG-IFN, as well as both PEG-IFN and ribavirin, accelerated the chance of SVR (Table 3).

#### Discussion

In a retrospective study, response to PEG-IFN and ribavirin for 48 weeks was compared between 179 men and 121 women with chronic hepatitis C who had been infected with HCV-1b in high viral loads by the Japanese definition ( $> 100$  kIU/ml) [14, 15]. Loss of HCV RNA from serum occurred less often in women than in men throughout the 48 weeks of treatment. Both ETR (55% vs 83%,  $P < 0.001$ ) and SVR (27% vs 59%,  $P < 0.001$ ) were achieved significantly less frequently in women than in men. The observed low response to PEG-IFN and ribavirin stands at odds with the better response to antiviral treatments and slow progression of fibrosis in women than in men [9, 16, 17]. There are, however, viral and host factors other than gender that can influence the course of chronic hepatitis C and, by inference, the response to antiviral treatments.

Viral factors such as HCV genotypes and infection load affect the course of chronic hepatitis C. Thus, hepatitis is

**Table 3** Factors promoting the response to PEG-IFN and ribavirin in multivariate analysis

Factors	Odds ratio	95% Confidence interval	P
Male gender	3.50	1.71–7.17	0.001
ICG <sub>15</sub> ≤ 13.5%	2.09	1.07–4.08	0.031
Ribavirin ≥ 11.1 mg/kg per day	2.17	1.11–4.25	0.024
Total PEG-IFN ≥ 80%	6.96	2.26–21.4	0.001
PEG-IFN/ribavirin ≥ 80%	12.66	2.32–71.4	0.003

more severe and less responsive to IFN in patients infected with HCV genotypes 1 and 4 than in those with HCV genotypes 2, 3 and 6 [18–22]. Likewise, high viral loads are associated with rapid progression of liver disease and poor response to IFN [23–25]. In our study, such viral factors were excluded in comparing the response to PEG-IFN and ribavirin between women and men. All the patients were infected with HCV genotype 1b in high viral loads (>100 kIU/ml).

Age influences the severity of chronic hepatitis C [9, 26], and disease progresses faster and response to antiviral therapy is poorer in older patients [23]. There were significant differences in age between female and male patients in our study. The women were older than the men [mean (range) 57 (30–69) years vs 50 (19–66) years,  $P < 0.001$ ], and the proportion of patients ≥60 years was higher in women than in men (39% vs 19%,  $P < 0.001$ ). Hence, the response to PEG-IFN and ribavirin was evaluated in patients aged ≥50 years and <50 years separately. There were no differences in the response between female and male patients <50 years, during and at the end of the 48-week treatment, as well as 24 weeks thereafter. However, ETR (55% vs 84%,  $P < 0.001$ ) and SVR (22% vs 53%,  $P < 0.001$ ) were gained significantly less often in women than men who were aged ≥50 years.

The influence of gender was observed, also, in patients aged ≥60 years and those aged 50–60 years. Hence, women would become less responsive than men to PEG-IFN and ribavirin after they had entered their fifties.

From a therapeutic notion, compliance with treatment can alter the response. Since ribavirin accumulates in erythrocytes and induces hemolysis, it is less tolerated in women who tend to be anemic than men without such an inclination [27]. At the baseline, women had lower levels of hemoglobin and ferritin than men. These would have been responsible for the lower tolerance to PEG-IFN and ribavirin in women than men in our study. In fact, ≥80% of the dose of PEG-IFN, ribavirin, or both, was tolerated less frequently in women than men ( $P < 0.001$  for each). Even in the patients who had received ≥80% of the dose, however, the response to PEG-IFN and ribavirin was gained less frequently in women than in men. Again, the

difference was due to a significantly lower response in female patients than in male patients aged ≥50 years, while the response was no different between those <50 years of age.

Taken altogether, the poorer response to PEG-IFN and ribavirin in women than in men was attributable to impaired response in the female patients aged ≥50 years. Older women with chronic hepatitis C, therefore, would be less responsive to the combined treatment with PEG-IFN and ribavirin currently in use. In support of this view, the response to human lymphoblastoid IFN for 24 weeks is dependent on gender and age [28]. The greatest physiological change precipitated in women by aging is a decreased serum concentration of bioavailable estrogen after they enter the menopause [29]. Estrogen has been shown to have an antifibrotic potential in both experimental and clinical studies. In experimental cirrhosis induced by dimethylnitrosamine in rats, administration of neutralizing antibodies to estradiol and ovariectomy enhanced fibrogenesis in female rats [30]. Hepatocytes have the receptor to estrogen [31], and myofibroblastic transformation in hepatic stellate cells of rats is inhibited in culture supplemented with this hormone [32]. Consequently, hepatic fibrosis progresses faster in menopausal women with chronic hepatitis C, and hormone replacement therapy may be able to prevent it [33]. Furthermore, in women aged ≥50 years, the number of estrogen receptor in hepatocytes decreases to one-half of that in those aged <50 years. This would stand in further support of the notion that the antifibrotic effects of decreased estrogen levels in patients aged ≥50 years with chronic hepatitis C would produce a lesser response to PEG-IFN and ribavirin.

Favorable effects of female sex hormones on hepatitis have long been suggested. Chronic hepatitis C is mild in menstruating women [34]; its activity is suppressed during pregnancy and enhanced after delivery [35]. The velocity of fibrosis progression is extremely low in young women exposed to HCV through mass-administration of immunoglobulin-D. Only two of 184 (1.2%) and four of 1,018 (0.4%) developed cirrhosis over 24 years and 20 years, respectively, in Irish and German studies [36, 37]. It does need to be pointed out, however, that the majority of women in those studies had not been followed beyond the menopause. There is a possibility that chronic hepatitis C may progress at a faster speed during their next few decades. Continued observations of them would be necessary to evaluate the validity of such an assumption.

Although decreased levels of estrogen can explain the enhanced activity of chronic hepatitis C in older women, as well as their concomitant resistance to PEG-IFN and ribavirin, it does not give an account of the better response in men than women who were aged ≥50 years. Feminization represented by gynecomastia is common in men

who have developed cirrhosis, and it can increase even in healthy men with age [38]. Possibly in the background of this phenomenon, circulating levels of free estrogen in men exceed those in women, after they enter their fifties, with margins widening with age [29]. It is tempting to speculate that elevated estrogen levels in men with chronic hepatitis C are responsible for their better response to the combination therapy than women who were aged  $\geq 50$  years. Whether or not such a speculation would hold would have to be evaluated by a comparison of estrogen levels between older men and women with chronic hepatitis C.

Although osteoporosis is an extrahepatic manifestation of chronic hepatitis C [39], hormone replacement therapy has been withheld for fear of potential hepatotoxicity. There is evidence, however, that oral contraceptives inhibit the progression of fibrosis in women [33]. It may lead to the possibility that the response to antiviral treatment in older women with chronic hepatitis C would be improved by substituting estrogen in them. The merit of hormone replacement therapy for them, of course, would need to be balanced against any harmful effects associated with it.

There are limitations in this study. All the patients were infected with genotype 1b in high viral loads. Hence, the results obtained may or may not be extended to patients with chronic hepatitis C who are infected with HCV of other genotypes in low viral loads. The influence of sex hormones needs to be substantiated by their determination in correlation with SVR. These limitations notwithstanding, the results obtained warrant a special caution in the treatment of women older than 50 years due to their lesser responsiveness to PEG-IFN and ribavirin.

**Acknowledgment** This study was supported, in part, by grants from the Ministry of Health, Labour and Welfare of Japan.

## References

- Cohen J. The scientific challenge of hepatitis C. *Science*. 1999;285:26–30. doi:10.1126/science.285.5424.26.
- Alberti A, Chemello L, Benvenuto L. Natural history of hepatitis C. *J Hepatol*. 1999;31:S17–S24. doi:10.1016/S0168-8278(99)80369-9.
- Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. *Semin Liver Dis*. 2000;20:17–35. doi:10.1055/s-2000-9505.
- Seeff LB. Natural history of chronic hepatitis C. *Hepatology*. 2002;36:S35–S46. doi:10.1002/hep.1840360706.
- Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. *Gastroenterology*. 1995;108:1088–1096. doi:10.1016/0016-5085(95)90207-4.
- Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. *Am J Gastroenterol*. 1997;92:1130–1134.
- Pageaux GP, Ducos J, Mondain AM, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. *Liver Transpl Surg*. 1997;3:501–505. doi:10.1002/lt.500030504.
- Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *N Engl J Med*. 1999;340:1228–1233. doi:10.1056/NEJM199904223401602.
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet*. 1997;349:825–832. doi:10.1016/S0140-6736(96)07642-8.
- Vogt M, Lang T, Prosser G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med*. 1999;341:866–870. doi:10.1056/NEJM199909163411202.
- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med*. 1998;339:1485–1492. doi:10.1056/NEJM199811193392101.
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002;347:975–982. doi:10.1056/NEJMoa020047.
- Hung CH, Lee CM, Lu SN, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. *Liver Int*. 2006;26:1079–1086. doi:10.1111/j.1478-324X.2006.01354.x.
- Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol*. 2007;79:1686–1695. doi:10.1002/jmv.20979.
- Sezaki H, Suzuki F, Kawamura Y, et al. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. *Hepatol Res*. 2007;37:787–792. doi:10.1111/j.1478-324X.2007.01352.x.
- Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology*. 2006;131:470–477. doi:10.1053/j.gastro.2006.06.008.
- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet*. 1998;352:1426–1432. doi:10.1016/S0140-6736(98)07124-4.
- Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. *Hepatology*. 1994;19:1088–1094.
- Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*. 2004;140:346–355.
- Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. *J Infect Dis*. 2003;187:1071–1074. doi:10.1086/368217.
- Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *J Med Virol*. 2005;77:66–69. doi:10.1002/jmv.20414.
- Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6

- than genotype 1 in Hong Kong. *Intervirology*. 2006;49:96–98. doi:10.1159/000087270.
23. Kumada T, Toyoda H, Honda T, et al. Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. *Intervirology*. 2006;49:112–118. doi:10.1159/000087273.
  24. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*. 2000;132:296–305.
  25. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. *J Viral Hepat*. 2000;7:250–257. doi:10.1046/j.1365-2893.2000.00233.x.
  26. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. *Gut*. 2002;51:248–252. doi:10.1136/gut.51.2.248.
  27. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. *J Gastroenterol*. 2004;39:668–673. doi:10.1007/s00535-003-1363-9.
  28. Hayashi J, Kishihara Y, Ueno K, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. *Arch Intern Med*. 1998;158:177–181. doi:10.1001/archinte.158.2.177.
  29. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. *J Clin Endocrinol Metab*. 1998;83:2266–2274. doi:10.1210/jc.83.7.2266.
  30. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. *Hepatology*. 1999;29:719–727. doi:10.1002/hep.510290307.
  31. Rossini GP, Baldini GM, Villa E, Manenti F. Characterization of estrogen receptor from human liver. *Gastroenterology*. 1989;96:1102–1109.
  32. Shiba M, Shimizu I, Yasuda M, Ii K, Ito S. Expression of type I and type III collagens during the course of dimethylnitrosamine-induced hepatic fibrosis in rats. *Liver*. 1998;18:196–204.
  33. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology*. 2004;40:1426–1433. doi:10.1002/hep.20463.
  34. Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women. *J Gastroenterol Hepatol*. 2000;15:1411–1417. doi:10.1046/j.1440-1746.2000.02368.x.
  35. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. *J Gastroenterol Hepatol*. 2000;15:175–181. doi:10.1046/j.1440-1746.2000.02060.x.
  36. Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. *Clin Gastroenterol Hepatol*. 2006;4:1271–1277. doi:10.1016/j.cgh.2006.05.028.
  37. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *Hepatology*. 2000;32:91–96. doi:10.1053/jhep.2000.8169.
  38. Braunstein GD. Gynecomastia. *N Engl J Med*. 1993;328:490–495. doi:10.1056/NEJM199302183280708.
  39. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. *Liver Transpl*. 2003;9:1166–1173. doi:10.1053/jlts.2003.50242.

# Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C

Yasuji Arase, Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Masahiro Kobayashi, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Miharuru Hirakawa, Kenji Ikeda, and Hiromitsu Kumada

Diabetes is present in patients with chronic hepatitis C virus infection. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for type 2 diabetes after the termination of interferon therapy in Japanese patients positive for hepatitis C virus (HCV). A total of 2,842 HCV-positive patients treated with interferon (IFN) monotherapy or combination therapy with IFN and ribavirin were enrolled. The mean observation period was 6.4 years. An overnight (12-hour) fasting blood sample or a casual blood sample was taken for routine analyses during follow-up. The primary goal was the onset of type 2 diabetes. Evaluation was performed by using the Kaplan-Meier method and Cox proportional hazard analysis. Of 2,842 HCV patients, 143 patients developed type 2 diabetes. The cumulative development rate of type 2 diabetes was 3.6% at 5 years, 8.0% at 10 years, and 17.0% at 15 years. Multivariate Cox proportional hazard analysis revealed that type 2 diabetes development after the termination of IFN therapy occurred when histological staging was advanced (hazard ratio 3.30; 95% confidence interval [CI] 2.06-5.28;  $P < 0.001$ ), sustained virological response was not achieved (hazard ratio 2.73; 95% CI 1.77-4.20;  $P < 0.001$ ), the patient had pre-diabetes (hazard ratio 2.19; 95% CI 1.43-3.37;  $P < 0.001$ ), and age was  $\geq 50$  years (hazard ratio 2.10; 95% CI 1.38-3.18;  $P < 0.001$ ). **Conclusion:** Our results indicate sustained virological response causes a two-thirds reduction in the risk of type 2 diabetes development in HCV-positive patients treated with IFN. (HEPATOLOGY 2009;49:000-000.)

**H**epatitis C virus (HCV) is one of the more common causes of chronic liver disease in world. Chronic hepatitis C is an insidiously progressive form of liver disease that relentlessly but silently progresses to cirrhosis in 20% to 50% of cases over a period of 10 to 30 years.<sup>1-3</sup> In addition, HCV is a major risk for hepatocellular carcinoma (HCC).<sup>4-8</sup> Moreover, chronic HCV infection has been associated with a variety of extrahepatic complications such as essential mixed cryoglobulinemia, porphyria cutanea tarda, membranoproliferative glomerulonephritis, autoimmune thyroid-

itis, sialadenitis, and cardiomyopathy.<sup>9-13</sup> Lately, data supporting a link between type 2 diabetes mellitus (T2DM) and chronic hepatitis C infection have been reported.<sup>14,15</sup>

Although there is growing evidence to support the concept that HCV infection is a risk factor for developing T2DM, there have been a few interventional studies confirming this issue. This issue needs to be confirmed with a long-term follow-up of patients with high risk of developing diabetes. Thus, prospective studies including metabolic evaluations are clearly needed to clarify these issues.

With this background in mind, the cohort study was initiated to investigate the cumulative incidence and risk factors of T2DM after prolonged follow-up in HCV-infected patients treated with interferon (IFN) monotherapy or combination therapy with IFN and ribavirin. The strengths of the current study are the large numbers of patients included and the long-term follow-up of patients.

## Patients and Methods

**Patients.** There were 5,890 patients diagnosed with chronic HCV infection and treated with IFN mono-

Abbreviations: CI, confidence interval; FPG, fasting plasma glucose; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; SVR, sustained virological response; T2DM, type 2 diabetes mellitus.

From the Department of Hepatology, Toranomon Hospital, Tokyo, Japan.

Received September 25, 2008; accepted October 13, 2008.

Supported in part by grants-in-aid from Okinaka Memorial Institute for Medical Research and the Japanese Ministry of Health, Labor, and Welfare.

Address reprint requests to: Yasuji Arase, M.D., Department of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan.

E-mail: es9y-ars@asahi-net.or.jp; fax: (81)-3-3582-7068.

Copyright © 2008 by the American Association for the Study of Liver Diseases.

Published online in Wiley InterScience (www.interscience.wiley.com).

DOI 10.1002/hep.22703

Potential conflict of interest: Nothing to report.

therapy or combination IFN + ribavirin therapy between September 1990 and March 2007 in the Department of Hepatology, Toranomon Hospital, Tokyo, Japan. Of these, 2,842 patients satisfied the following criteria: (1) no evidence of diabetes mellitus for 3 months after the termination of IFN (plasma glucose concentration <126 mg/dL [6.9 mmol/L] in the fasting state, <200 mg/dL [11.0 mmol/L] in casual state and/or 2 hours after a 75-g oral glucose load); (2) features of chronic hepatitis or cirrhosis diagnosed via laparoscopy and/or liver biopsy before the initiation of IFN therapy; (3) positivity for serum HCV RNA before the initiation of IFN therapy; (4) period of  $\leq 1$  year of IFN therapy; (5) negativity for hepatitis B surface antigen (HBsAg), antinuclear antibodies, or antimitochondrial antibodies in serum, as determined via radioimmunoassay or spot hybridization; (6) no evidence of HCC nodules as shown on ultrasonography and/or computed tomography; and (7) no underlying systemic disease, such as systemic lupus erythematosus or rheumatic arthritis.

Patients who were taking medications known to alter glucose tolerance or had illnesses that could seriously reduce their life expectancy or their ability to participate in the trial were excluded from the study. Patients were classified as having normal glucose or pre-diabetes based on fasting plasma glucose (FPG), casual plasma glucose, or 2-hour plasma glucose. The normal glucose group was regarded as having an FPG of <100 mg/dL, casual plasma glucose of <140 mg/dL, and/or 2-hour plasma glucose of <140 mg/dL. The pre-diabetes group was regarded as having an FPG of 100-125 mg/dL, casual plasma glucose of 140-200 mg/dL, and/or 2-hour plasma glucose of 140-200 mg/dL.<sup>16</sup>

Next, we assessed predictive factors for T2DM in chronic hepatitis C patients treated with IFN. The physicians in charge explained the purpose and method of this clinical trial to each patient and/or the patient's family. Informed consent was obtained from all living patients included in the present cohort study. The study was approved by the Institutional Review Board of our hospital.

**Outcome Measures.** The primary outcome was T2DM, diagnosed by the use of the 2003 criteria of the American Diabetes Association.<sup>16</sup> These criteria include (1) casual plasma glucose  $\geq 200$  mg/dL; (2) FPG  $\geq 126$  mg/dL; (3) 2-hour post-glucose (oral glucose tolerance test)  $\geq 200$  mg/dL.

**Laboratory Investigation.** Anti-HCV was detected using a second-generation enzyme-linked immunosorbent assay (ELISA II; Abbott Laboratories, North Chicago, IL). HCV-RNA was determined by the Amplicor method (Cobas Amplicor HCV Monitor Test, version 2.0; Roche, Tokyo, Japan). Hepatitis B surface antigen was tested via radioimmunoassay (Abbott Laboratories, Detroit, MI). The used serum samples were stored at

-80°C at the first consultation. Diagnosis of HCV infection was based on detection of serum HCV antibody and positive RNA. Height and weight were recorded at baseline, and the body mass index was calculated as weight (in kg)/height (in m<sup>2</sup>).

**Evaluation of Liver Cirrhosis.** Liver status of the 2,842 patients was mainly determined via peritoneoscopy and/or liver biopsy. Liver biopsy specimens were obtained using a modified Vim Silverman needle with an internal diameter of 2 mm (Tohoku University, Kakinuma Factory, Tokyo, Japan), fixed in 10% formalin, and stained with hematoxylin-eosin, Masson's trichrome, silver impregnation, and periodic acid-Schiff after diastase digestion. The size of specimens for examination was more than six portal areas.<sup>17</sup>

**Follow-up.** The starting time of follow-up was 3 months after the termination of IFN therapy. After that, patients were followed up monthly to tri-monthly in our hospital. Physical examination and biochemical tests were conducted at each examination together with regular check-up. An overnight (12-hour) fasting blood sample or a casual blood sample was taken for routine analyses. These included aminotransferase activities, total cholesterol, platelet counts, and serum HCV RNA level. Three hundred twenty-four patients were lost to follow-up; because the appearance of T2DM and death was not identified in these patients, they were considered as censored data in the statistical analysis.<sup>18</sup> Moreover, patients retreated with antiviral agents were regarded as withdrawals at the time of starting the retreatment of antiviral agents.

**Statistical Analysis.** The cumulative appearance rate of T2DM was calculated from 3 months after the termination of IFN treatment to the appearance of T2DM using the Kaplan-Meier method. Differences in the development of T2DM were tested using the log rank test. Independent factors associated with the incidence rate of T2DM were analyzed by the Cox proportional hazard model. The following 11 variables were analyzed for potential covariates for incidence of T2DM at the time of termination of IFN therapy at our hospital: age, sex, state of liver disease (chronic hepatitis or liver cirrhosis), body mass index, glucose level, aspartate aminotransferase level, alanine aminotransferase level, type of IFN, total dose of IFN, efficacy of IFN therapy, hypertension, triglyceride level, and total cholesterol level. A *P*-value of less than 0.05 was considered significant. Data analysis was performed using SPSS 11.5 for Windows (SPSS, Chicago, IL).

## Results

**Patient Characteristics.** Table 1 shows the characteristics of the 2,842 HCV-positive patients treated with

**Table 1. Patient Characteristics**

N	2,842
Sex (male/female)	1,778/1,064
Age (years)	51.8 ± 9.0
Height (cm)	163.8 ± 9.1
Body weight (kg)	62.7 ± 11.7
Body mass index	23.3 ± 3.2
Blood pressure (systolic/diastolic, mm Hg)	128 ± 18/77 ± 12
HCV genotype (1b/2a/2b/other)	744/752/290/56
HCV RNA level (KIU/mL)	593 ± 540
Staging (non-LC/LC)	2,649/193
Blood glucose level (normal/prediabetes)	2,601/241
Fasting plasma glucose (mg/dL)	87 ± 24
Triglyceride (mg/dL)	166 ± 31
Total bilirubin (g/dL)	102 ± 56
AST (IU/L)	74 ± 63
ALT (IU/L)	116 ± 102
IFN monotherapy*/combination therapy†	2,417/425
Efficacy of treatment (SVR/non-SVR)	1,175/1,667
Follow-up period (years)	6.4 ± 5.0

Data are expressed as the number of patients or mean ± standard deviation. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LC, liver cirrhosis; SVR, sustained virological response.

\*Outbreak of IFN monotherapy: recombinant IFN- $\alpha$ 2a, 304 cases; recombinant IFN- $\alpha$ 2b, 235 cases; natural IFN- $\beta$ , 1,355 cases; natural IFN- $\beta$ , 522 cases; total dose of IFN = 598 ± 170 MU.

†Outbreak of combination therapy: recombinant IFN- $\alpha$ 2b + ribavirin, 175 cases; total dose of IFN = 537 ± 196 MU; total dose of ribavirin = 182 ± 69 g; pegylated IFN- $\alpha$ 2b + ribavirin, 250 cases; total dose of pegylated IFN = 4.28 ± 1.17 mg; total dose of ribavirin = 232 ± 60 g.

IFN monotherapy or combination therapy with IFN and ribavirin. The sustained virological response (SVR) rate was 36.7% (886/2417) in IFN monotherapy and 68% (289/425) in IFN + ribavirin therapy. Thus, the number of patients with SVR was 1,175. The mean period after the termination of antiviral drugs was 6.4 years.

**Incidence of T2DM in Patients with HCV.** A total of 143 patients (102 men and 41 women) developed T2DM during a mean observation period of 6.4 years. Of these, 26 were SVR and 117 were non-SVR. The cumulative development rate of T2DM was determined to be 3.6% at 5 years, 8.0% at 10 years, and 17.0% at 15 years using the Kaplan-Meier method (Fig. 1). The factors associated with the incidence of T2DM in all 2,842 patients treated with IFN therapy are shown in Table 2.

Multivariate Cox proportional hazard analysis revealed that type 2 diabetes development after the termination of IFN therapy occurred when histological staging was advanced (hazard ratio 3.30; 95% confidence interval [CI] 2.06-5.28;  $P < 0.001$ ), sustained virological response was not achieved (hazard ratio 2.73; 95% CI 1.77-4.20;  $P < 0.001$ ), patient had pre-diabetes (hazard ratio 2.19; 95% CI 1.43-3.37;  $P < 0.001$ ), and age was  $>50$  years (hazard ratio 2.10; 95% CI 1.38-3.18;  $P < 0.001$ ). SVR causes a two-thirds reduction of development of T2DM in patients treated with IFN. In addition to SVR, age  $\geq 50$

years, liver cirrhosis, and pre-diabetes contribute to a high risk of developing diabetes. The cumulative development rates of T2DM based on difference of age, efficacy of the IFN therapy, histological diagnosis, and glucose level at the starting time of follow-up are shown in Fig. 2.

Fig. 3 shows the impact of reduction due to SVR on the incidence of T2DM in patients with  $\geq 50$  years, liver cirrhosis, or pre-diabetes. When patients with age  $\geq 50$  years, liver cirrhosis, and pre-diabetes have SVR after IFN therapy, SVR could statistically reduce the onset of T2DM compared with those without SVR.

## Discussion

We have described the development incidence of diabetes after the termination of antiviral therapy in HCV-positive patients treated with IFN therapy in the present study. Diabetes has been reported in less than 0.08% of patients treated with IFN<sup>19,20</sup>; thus, to exclude diabetes originating from IFN-related side effects, patients without diabetes for 3 months after the termination of IFN were enrolled in the present study. The present study indicates that the annual incidence of T2DM for a prolonged follow-up after the termination of IFN therapy among HCV patients is 0.8% to 1.0%. The present study was limited by a retrospective cohort trial. We started the present study in 1991 based on the diabetes mellitus criteria published by Fajans.<sup>21</sup> However, after that, diabetes mellitus criteria were revised. We thus rechecked the diagnosis of T2DM based on the diabetes mellitus criteria of 2003 in patients seen prior to 2003.<sup>16</sup> Because of rechecking the diagnosis of T2DM on the basis of diabetes mellitus criteria in 2003, the present study was regarded as a retrospective cohort study. However, the patients were




Fig. 1. Cumulative development rate of T2DM in patients treated with IFN.

Table 2. Predictive Factors for T2DM Development

Variables	Univariate Analysis		Cox Regression	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Age, years ( $\geq 50$ / $<50$ )	2.55 (1.74-3.73)	$<0.001$	2.10 (1.38-3.18)	$<0.001$
Sex (female/male)	0.84 (0.59-1.19)	0.318		
Body mass index ( $\geq 25$ / $<25$ )	1.44 (0.98-2.08)	0.057		
HCV load (KIU/mL)				
$\geq 1,000$ / $<1,000$	0.67 (0.43-1.03)	0.069		
Genotype (1/2)	0.73 (0.50-1.06)	0.098		
ALT (IU/L, $\geq 50$ / $<50$ )	1.83 (1.14-2.94)	0.012		
Glucose level (prediabetes/normal)	2.25 (1.53-3.33)	$<0.0001$	2.19 (1.43-3.37)	$<0.001$
Triglyceride (mg/dL, $\geq 150$ / $<150$ )	1.66 (0.93-2.98)	0.088		
Cholesterol (mg/dL, $\geq 220$ / $<220$ )	1.56 (0.62-3.95)	0.346		
Histological diagnosis (LC/non-LC)	4.03 (2.55-6.36)	$<0.0001$	3.30 (2.06-5.28)	$<0.001$
Combination of ribavirin (-/+)	1.53 (0.99-2.38)	0.058		
Type of IFN ( $\alpha$ / $\beta$ )	0.88 (0.57-1.35)	0.882		
Total dose of IFN (MU, $\geq 500$ / $<500$ )	0.91 (0.59-1.40)	0.672		
Efficacy (non-SVR/SVR)	2.73 (1.77-4.20)	$<0.0001$	2.78 (1.75-4.41)	$<0.001$

Data are expressed as the median (range).

Abbreviations: ALT, alanine aminotransferase; HR, hazard ratio; LC, liver cirrhosis.

prospectively followed. Another limitation of the study was that patients were treated with different types of antiviral therapy (IFN monotherapy or combination IFN + ribavirin therapy) for different duration (4 to 52 weeks).

This heterogeneity makes it difficult to interpret the results of the study. On the other hand, the strength of the present study is the long-term follow-up in the large numbers of patients included.




Fig. 2. Cumulative development rate of T2DM in patients treated with IFN. (A) Cumulative development rate of T2DM based on difference of hepatic fibrosis. (B) Cumulative development rate of T2DM based on the difference of glucose level. (C) Cumulative development rate of T2DM based on the difference of efficacy. (D) Cumulative development rate of T2DM based on the difference of age.






Fig. 3. Cumulative development rate of T2DM in patients with SVR or without SVR after IFN therapy. (A) Cumulative development rate of T2DM based on SVR or non-SVR in patients with age  $\geq 50$  years. (B) Cumulative development rate of T2DM based on SVR or non-SVR in patients with liver cirrhosis. (C) Cumulative development rate of T2DM based on the difference of SVR or non-SVR in patients with pre-diabetes.

The present study shows several findings with regard to development of T2DM after the termination of antiviral agents for HCV positive patients. First, the T2DM development rate in the non-SVR group was higher than that in the SVR group. The SVR caused a two-thirds reduction in the onset of T2DM in the course of posttreatment follow-up. That SVR reduced the onset of diabetes mellitus in HCV patients is in accordance with the data reported by Simó et al.<sup>22</sup> and Romero-Gómez et al.<sup>23</sup> Though the role of HCV in the pathogenesis of diabetes mellitus remains speculative, the following possible mechanisms have been reported: (1) patients with HCV have a tendency to attain insulin resistance<sup>24</sup>; (2) in transgenic mice, the expression of HCV core protein is associated with insulin resistance and T2DM development<sup>25</sup>; and (3) SVR in HCV patients reduces insulin resistance and onset of the incidence of abnormal glucose value.<sup>26</sup> Thus, it is accepted that clearance of HCV reduces the onset of T2DM.

Second, in addition to persistence of HCV, the present study suggests that aging, histological progression, and pre-diabetes enhanced the onset of T2DM in patients with HCV infection. However, when HCV was eradicated even in patients with age  $\geq 50$  years, pre-diabetes, or liver cirrhosis, the cumulative development rate of T2DM decreased.

T2DM is increasing dramatically in many Asian nations, including Japan, over the past decades.<sup>27</sup> It is widely accepted that 7 to 8 million people are affected by diabetes mellitus in Japan. Approximately 8% to 10% of adults in Japan have T2DM. In general, T2DM is associated with a genetic predisposition, but it is also strongly influenced by lifestyle-related factors, such as eating habits and/or physical activity.<sup>28-33</sup> The risk factors associated with T2DM include family history, age, sex, obesity, smoking, and physical activity. T2DM occurred in elderly patients

compared to young patients. Life expectancies are long in Japan; thus, in the near future, a large number of patients with HCV will be  $>60$  years of age. Therefore, it is apparent that the incidence of T2DM will increase in HCV-positive patients.

T2DM is a serious, costly disease. Treatment for T2DM may prevent some of its devastating complications, but does not usually restore normoglycemia or eliminate all the adverse consequences.<sup>28,29</sup> Moreover, HCV patients with T2DM are at major risk for HCC.<sup>34</sup> On the efficacy of IFN therapy, it has been reported that T2DM reduces HCV eradication via combination IFN + ribavirin therapy.<sup>26</sup> Thus, it should be considered whether HCV-positive patients should be treated with antiviral drugs in the histological nonprogression stage and at a non-elderly age for prevention of T2DM onset. If SVR obtained via antiviral therapy for HCV cannot only prevent progression to liver cirrhosis or HCC but also prevent the development of diabetes, the potential impact of IFN therapy is quite significant.

In conclusion, this retrospective study suggests that the annual incidence of T2DM among patients with HCV is 0.8% to 1.0%. Our results indicate that SVR causes a two-thirds reduction of T2DM development in HCV-positive patients treated with antiviral drugs.

**Acknowledgment:** The authors acknowledge the editorial assistance of Thomas Hughes.

## References

- Kiyosawa K, Furuta S. Review of hepatitis C in Japan. *J Gastroenterol Hepatol* 1991;6:383-391.
- Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community acquired hepatitis C in the United States. *N Engl J Med* 1992;327:1899-1905.
- van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. *Aliment Pharmacol Ther* 1998;12:199-205.

4. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. *Lancet* 1989;2:1006-1008.
5. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, et al. Hepatitis C-associated hepatocellular carcinoma. *HEPATOLOGY* 1990;12:589-591.
6. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. *Lancet* 1990;335:873-874.
7. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med* 1993;328:1797-1801.
8. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. *HEPATOLOGY* 1993;18:47-53.
9. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease—review of extrahepatic manifestations. *Ann Intern Med* 1995;123:615-620.
10. Johnson RJ, Gretsch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* 1993;328:465-470.
11. Pawlowsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, André C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. *Ann Intern Med* 1995;122:169-173.
12. Boadas J, Rodriguez-Espinosa J, Enriquez J, Miralles F, Martínez-Cerezo FJ, González P, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. *J Hepatol* 1995;22:611-615.
13. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. *N Engl J Med* 1992;327:1490-1495.
14. Imazeki F, Yokosuka O, Fukui K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. *Liver Int* 2008;28:355-362.
15. Arai M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. *J Gastroenterol* 2003;38:355-360.
16. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003;26:3160-3167.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *HEPATOLOGY* 1994;19:1513-1520.
18. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. *Control Clin Trials* 1984;5:348-361.
19. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. *J Hepatol* 1998;28:514-517.
20. di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scoglio R, et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. *Dig Dis Sci* 1996;41:1672-1677.
21. Fajans S. Classification and diagnosis of diabetes. In: Rifkin H, Porte D, eds. *Diabetes Mellitus: Theory and Practice*. 4th ed. New York: Elsevier, 1990:346-356.
22. Simó R, Lecube A, Genesà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. *Diabetes Care* 2006;29:2462-2466.
23. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. *J Hepatol* 2008;48:721-727.
24. Romero-Gómez M. Insulin resistance and hepatitis C. *World J Gastroenterol* 2006;12:7075-7080.
25. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004;126:840-848.
26. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 2005;128:636-641.
27. Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, Isogawa A, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. *Diabet Med* 2005;22:323-331.
28. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race: a case-control study. *Am J Gastroenterol* 2003;98:438-441.
29. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. *HEPATOLOGY* 2003;38:50-56.
30. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047-1053.
31. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-853.
32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854-865.
33. Elbein SC. The search for genes for type 2 diabetes in the post-genome era. *Endocrinology* 2002;143:2012-2018.
34. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. *HEPATOLOGY* 2008;47:1856-1862.

## 特集/肝機能検査値—その上手な読み方

## 検査値の読み方

## 肝炎ウイルスマーカー

林 純 古 庄 憲 浩

## はじめに

肝炎ウイルスとして、現在A, B, C, D, E, G型およびTTVが認められている。A型肝炎ウイルスを(Hepatitis A Virus: HAV), B型肝炎ウイルスを(Hepatitis B Virus: HBV), 以下同様にしてHCV, HDV, HEV, HGVと記す。HBVはDNAウイルスであるが、その他はRNAウイルスであり、HAVおよびHEVは経口感染であるが、その他は主として血液を介した感染である。

これらウイルス肝炎のウイルスマーカーの意義を理解することは、ウイルスに感染した時期、肝炎の状態および他人への感染性などを予測することができ、臨床的に有用と考えられる。なお、現在HGVおよびTTVは肝炎との関連性が明確でないため、本稿では省略する。

## I. A型肝炎

## 1. ウイルスの特徴

HAVはエンベロープを有さない直径27nmの正20面体の粒子で、ウイルスの分類上ではピコルナウイルス科に属し、エンテロウイルス72型に分類されている。その蛋白は5種類の構造と6種類の非構造蛋白からなる。また、ウイルスのゲノムとしては約7.5kbの線状1本鎖RNAであることが知られ、その全塩基配列が明らかにされている。

## 2. ウイルスマーカーと臨床経過

A型急性肝炎の臨床の特徴は、38℃以上の発熱をきたす率が高く、食欲不振、悪心、嘔吐などの消化器症状、全身倦怠感、黄疸も高頻度に見られるが、慢性化することはない。

A型肝炎は、血清中にIgM型HA抗体を検出することで診断される。IgM型HA抗体は、一

般にA型肝炎の発症早期より血中に出現し、3～6ヵ月間みられる。IgG型HA抗体はHAV感染がごく最近なものでも、かなり過去のものでも陽性となる。IgG型HA抗体のみで、A型肝炎の診断をする場合は、時期をおいて再検査し、抗体価の上昇を確認する必要がある。

## II. B型肝炎

## 1. ウイルスの特徴

HBVは直径42nmの粒子で、エンベロープとそれに囲まれた直径27nmの芯(コア)を有する二重構造をなしている。ウイルスのゲノムは約3.2kbの二本鎖環状DNAであるが、コア抗原(HBc抗原)、表面抗原(HBs抗原)、ポリメラーゼ、Xの4種の蛋白の遺伝子がコードされている。

## 2. ウイルスマーカーと臨床経過(図1)

B型急性肝炎の場合のHBV関連マーカーとしては、現在HBVDNAおよびHBVの遺伝子産物であるHBs抗原、HBe抗原、HBc抗原があり、感染宿主が産生するHBs抗体、HBe抗体、HBc抗体があるが、HBc抗原は肝細胞の中には存在するが、血液中には存在していない。

血液中のHBVDNA量はウイルス量そのものを表し、その増減はウイルスの複製の状態を示している。HBVDNAは血清アミノトランスフェラーゼ値が上昇する約2週間前に増加し、血清ア




図1 HBV関連のマーカーの推移

ミノトランスフェラーゼ値が下降する約2週間前には低下する。このような時間的ずれは、肝細胞にウイルスが増加することに対して、感染宿主の細胞障害性Tリンパ球が反応し、肝細胞が破壊され、その結果として血清アミノトランスフェラーゼ値が上昇するためと考えられる。すなわち、HBVDNA量の推移をみると、血清アミノトランスフェラーゼ値の推移を予測でき、インターフェロンの投与時期の決定などにも有用である<sup>1)</sup>。

HBs抗原の臨床的意義としては、現在HBVに感染していることを示しているのみで、それ以上の意義はない。しかし、HBVDNAに比較し測定が容易であり、またその感度も有意に高いため、HBV感染のスクリーニング検査としては有用である。また、HBs抗原量については、急性肝炎の回復期に有意に減少し、最終的に陰性となり、臨床的意義もあると思われるが、慢性肝炎などでのHBs抗原量の推移は血清アミノトランスフェラーゼ値の推移と関連はなく、臨床的意義は少ない。また、HBV持続感染者におけるHBs抗原は加齢とともに年間1%は陰性化する<sup>2)</sup>。

一般にHBs抗体はHBVの中和抗体とされ、感染防御に役立つ抗体であり、一般にHBs抗原が陰性化した後に陽性となり、その後持続して陽性であるが、陰性化することもある。また、HBワクチンによっても陽性となる<sup>3)</sup>。その一方で、HBs抗原陽性者、すなわちHBV持続感染者、の約15%は同時にHBs抗体も陽性である<sup>4)</sup>。その際のHBs抗体のsubtypeはHBs抗原と異なっていることから、subtypeの異なるHBVの重複感染、subtypeの変異による結果によるものと考えられたが<sup>4)</sup>、現在、このようなHBs抗原/抗体共存例の臨床的意義はないとされている。

HBe抗原はHBVが感染初期から中期に産生する蛋白で、感染後期ではHBVDNAのPrecore領域あるいはCorepromoter領域のpoint mutationによりHBVはHBe抗原の産生が中止される<sup>5)</sup>。そのためHBV持続感染者の血液中にはHBe抗原が陰性化しHBe抗体が陽性となるseroconversionがみられる。これはウイルス側からみると肝細胞に感染しているHBVが野生ウイルスから変異ウイルスに置き換わったことを意味している。HBe抗原はHBVの感染性の指標と考えられていたが、これは野生ウイルスの方が変異ウイルスより複製力が強く、血液中のHBV量が増加するためと思われる。最近、HBe抗原の役割とし

て感染宿主の細胞障害性Tリンパ球の活性化を抑制することが知られている<sup>6)</sup>。HBV持続感染者でHBe抗原量が減少してくると肝炎の急性増悪がおり、あるいはHBe抗原陰性のHBV感染者から感染した場合、劇症肝炎になる<sup>7)</sup>とされているが、これらのことは細胞障害性Tリンパ球の抑制解除と関連しているのかもしれない。

HBe抗原は、血液中にはHBVの中に存在し、HBs抗原に包まれているため測定できない。一方、HBe抗体は感染初期より陽性となり、その後HBs抗原が陽性の場合、必ず陽性であり、HBs抗原が陰性となっても陰性となることはない。上述したようにHBs抗体は陰性化することがしばしばみられるが、HBe抗体はHBVの感染が一度成立すると持続陽性を示すため、最も感度の良いHBVの感染マーカーといえる<sup>8)</sup>。

IgM型HBe抗体はHBVの感染初期に出現する抗体である。B型急性肝炎では早期にHBs抗原が陰性化することがあるが、IgM型HBe抗体は比較的長期に陽性であることから、診断の手助けとなる。一方、B型慢性肝炎の急性増悪でも陽性となることがあるが、その値は急性肝炎に比べて低い<sup>9)</sup>。

近年、血液中のHBe抗体は陽性であるが、HBs抗原およびHBVDNAは陰性で、現在HBVの感染が存在しないと考えられる例をドナーとして肝移植が行われた場合、レシブエントにB型急性肝炎(劇症肝炎)が発症することが知られている。すなわち、HBVにいったん感染すると血液中にはウイルスは存在しなくなった後でも、肝臓にはかなり長期に存在すると考えられている<sup>10)</sup>。

その他のマーカーとして、保険適応ではないがgenotype(AからG)の測定が容易になった。わが国では主としてBとCで、genotype Bの感染者は無症候性が多いのに比べ、Cは慢性肝炎、肝硬変、肝癌が多く予後不良である<sup>11)</sup>。最近、わが国では欧米で主流のgenotype Aが増加している<sup>12)</sup>。一般に成人でHBVに感染しても持続感染に移行しないが、genotype AのHBVに感染すると成人でも持続感染に移行するとされている。

現在、B型慢性肝炎に対してはラミブジンの投与が行われており、著者らの312例の3年間治療成績ではそのウイルス学的効果は6ヵ月後で85%みられたが、ラミブジン耐性ウイルスの出現による再燃があり、36ヵ月後で55%と減少していた。